Please login to the form below

Not currently logged in
Email:
Password:

Nordic Capital acquires ADVANZ PHARMA for $846m

ADVANZ PHARMA shareholders to receive $17.26 per share under the terms of the deal

Cidron Aida Bidco, a subsidiary of private equity investor Nordic Capital, has completed its acquisition of speciality pharma company ADVANZ PHARMA.

UK-based ADVANZ PHARMA has a strategic focus on complex medicines in Europe, with expertise in anti-infectives and endocrinology therapy areas.

The company, headquartered in London, has ‘strong relationships’ with hospital decision-makers and has a network of commercial partners across the globe.

The acquisition values the entire issued and to-be-issued limited voting share capital of the company at approximately $846m, with ADVANZ PHARMA shareholders to receive $17.26 per share under the terms of the deal – excluding Bybrook, the former shareholder of the company who chose an alternative offer and whose shares were exchanged for Topco B Shares.

"This deal is fantastic news for ADVANZ PHARMA and our goal of becoming the go-to partner for complex medicines in Europe,” said Graeme Duncan, chief executive officer of ADVANZ PHARMA.

“Nordic Capital will be pivotal in helping the business through both its deep sector expertise and access to capital that will enable considerable investment in our organic and inorganic pipeline. This partnership will be essential in allowing us to further broaden choice for both prescribers and patients throughout the world and ensure access to the essential medicines we supply,” he added.

"ADVANZ PHARMA's vision and regional focus fully aligns with Nordic Capital's expertise and deep knowledge of European market sectors. We are delighted to be able to support ADVANZ PHARMA at this exciting juncture in their journey,” said Raj Shah, partner and head of healthcare, Nordic Capital Advisors

“Nordic Capital will help fuel the company's strategic growth and allow it to invest in future pipeline and M&A activities so that even more patients can access critical medicines now and in the future,” he added.

Article by
Lucy Parsons

3rd June 2021

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Spirit, an OPEN Health Company

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...
Serious about sustainability?
Get to know our new Sustainability Officer here at Cuttsy+Cuttsy...
How scientific storytelling can help Pharma cut through the noise
Rather than being afraid of storytelling, pharmaceutical firms should be embracing it. Because what scientific storytelling allows us to do is to communicate quickly and efficiently. It provides a shortcut...